MET and non-small cell lung carcinoma: For patients with advanced or metastatic NSCLC featuring MET exon 14 skipping mutation, capmatinib and tepotinib are currently the preferred first-line treatments, whereas crizotinib is considered useful in specific cases.322 Based on the phase II GEOMETRY study, capmatinib as a first-line treatment resulted in a median PFS of 12.4 months,57 and in the phase II VISION study,323 tepotinib as a first-line treatment led to a median DOR of 46.6 months for previously untreated patients, though this duration reduced to 12.6 months for those who had previously received treatment.